Elanco Animal Health (NYSE:ELAN) Sets New 12-Month Low – What’s Next?

Elanco Animal Health Incorporated (NYSE:ELAN)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $10.20 and last traded at $10.19, with a volume of 1667596 shares changing hands. The stock had previously closed at $10.80.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Stifel Nicolaus cut their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Morgan Stanley reduced their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Finally, UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Trading Down 6.8 %

The firm has a market cap of $4.98 billion, a P/E ratio of 25.16, a P/E/G ratio of 2.50 and a beta of 1.44. The firm has a fifty day moving average of $11.60 and a 200-day moving average of $12.86. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $0.08 EPS. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently bought and sold shares of ELAN. Commerce Bank boosted its stake in shares of Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after acquiring an additional 741 shares in the last quarter. Hillsdale Investment Management Inc. lifted its stake in shares of Elanco Animal Health by 2.1% in the fourth quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company’s stock worth $524,000 after buying an additional 900 shares during the last quarter. Arizona State Retirement System grew its stake in Elanco Animal Health by 0.8% in the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company’s stock valued at $1,737,000 after buying an additional 1,166 shares during the last quarter. MTM Investment Management LLC raised its holdings in Elanco Animal Health by 9.3% in the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock worth $172,000 after acquiring an additional 1,200 shares during the period. Finally, M&T Bank Corp lifted its position in Elanco Animal Health by 5.9% during the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after acquiring an additional 1,464 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.